Home / Transcripts / Auna S.A. (AUNA) · May 20, 2026

Auna S.A. (AUNA) Earnings Call Transcript

May 20, 2026

New York Stock Exchange US Health Care Health Care Providers and Services earnings 59 min

Earnings Call Speaker Segments

Ana Maria Mora executive
#1

Thanks, operator. Hi, everyone, and welcome to Auna's conference call, where we'll go over our first quarter results. Just a heads-up that a webcast presentation is available to follow along with what we discuss on this call. If you'd like a copy of that presentation, it's on our Investor Relations website, or you can reach out to Auna's Investor Relations team. Also, when we talk about variances, they'll be presented on a year-over-year basis, in FX-neutral or local currency terms for Mexico and Colombia, unless we say otherwise. Let's turn to Slide 2. In addition to sharing unaudited financial results prepared under International Financial Reporting Standards, our discussion will also address select non-IFRS financial measures and operating metrics, among them foreign exchange neutral calculations. We urge investors to look over the definitions of these measures, along with the metrics and reconciliations included in our earnings press release, which came out yesterday once the market had closed, so that they grasp them completely. Non-IFRS financial measures and operating metrics ought not to be considered by themselves as a substitute for IFRS financial measures, nor as superior to them, and they are provided solely as supplementary information. Before we begin our comments, I want to note that certain things said in today's conversation might be forward-looking, reflecting what management currently expects and believes. A variety of risks and uncertainties could make actual outcomes turn out substantially different, including some factors that may lie beyond the company's control. This applies to, though is not confined to: our target leverage ratio; suppliers and information systems in Mexico; how the key initiatives we're carrying out in Mexico, Colombia and Peru turn out; the capacity and market Torre Trecca is expected to have once it is built; how our strategic plan gets executed, which includes restoring our growth levels and rolling out the AunaWay in Mexico; the investments we plan to make; the revenue growth and adjusted EBITDA growth we expect; our revenue and adjusted EBITDA guidance; and generating additional growth along with sustainable value for all stakeholders. If you want details about the risks that could impact what we say about future expectations, take a look at the Form 20-F we filed with the U.S. Securities and Exchange Commission, as well as the press release on our earnings. Let's pull up Slide 3. On the line with us today: Suso Zamora, who serves as Executive Chairman and President; Gisele Remy, our Chief Financial Officer and Executive Vice President; and Lorenzo Massart, Executive Vice President of Strategy and Equity Capital Markets. They're going to walk through Auna's consolidated and segment financial and operating results for the first quarter, plus give an update on the strategic growth initiatives we've been pursuing. Once they're done, we'll take your questions. Suso, over to you.

Jesús Zamora Leon executive
#2

Appreciate it, Annie. Slide 4, if you would. 2026 has begun well for us, as we built commercial momentum throughout our regional health care platform, sped up growth, and produced robust cash flows. Within Auna Mexico's hospital platform, we've steadied the business and brought growth back. At Auna Colombia's hospital platform, we've made it stronger by growing our distinctive risk-sharing operations and by going deeper in our ties with that nation's biggest and best-funded payers; meanwhile, revenue from Auna Peru's hospital platform keeps climbing, thanks to further expansion of our more complex services and rising plan memberships. What lies ahead is plain: make our model simpler; concentrate on the things we excel at; and broaden the reach of the AunaWay. Now on to our financials. Topline was up 10% FXN during the first quarter, as revenues rose in every segment. That said, because of 2 extraordinary items — which we'll cover in more detail later on — adjusted EBITDA fell 5% FXN and margin shrank 2.9 percentage points. Even so, we remain on track relative to our 2026 guidance. In Mexico, we saw greater service volumes, and utilization levels went up. Even more significant, utilization climbed within high complexity services, especially surgery and oncology. Mexico's operations came through as expected, with a 19% quarter-over-quarter lift in adjusted EBITDA. The Peru segment of our integrated platform did well, keeping up its growth momentum throughout the quarter in spite of adjustments tied to payer reconciliations, which hit revenue and, in turn, profitability. Revenues rose 9%, backed by solid volume growth in health care services, high complexity services among them, while OncoSalud kept bringing on new planned members via expanding B2B sales. In Colombia, we've mostly moved past the intervened payers, thanks to risk-sharing businesses and newly established payer relationships. Such distinctive agreements have reliably yielded more predictable topline and cash flow growth. A quick word on our balance sheet. Our leverage ratio stood at 3.7x. Cash rose 22% to PEN 409 million, and free cash flow came in 2.6x higher than the comparable period last year — a key signal of our capacity to fine-tune operations for effective cash management throughout our regional platform. Let's go to Slide 5. Rising volumes at greater capacity utilization levels in health care, together with more plan memberships, fueled the quarter's robust topline growth and cash flow. As the bottom left of this slide shows, total utilization rose 1.4 percentage points to 66%. Still, our aim is to lift utilization in higher-margin, high complexity services, not merely on-bed occupancy. In Peru, where our business is vertically integrated, health care plan memberships rose 6%, and oncology plans were up 3%. On top of that, the oncology MLR came in under 50%, inside its expected range. Run rate profitability across our regional platform also strengthened considerably during the quarter. To repeat, adjusted EBITDA declined 5% FXN, mostly because of revenue adjustments and certain payroll increases. Let's head to Slide 7 now for a closer look at how each segment of our platform performed, beginning with Mexico. Mexico really bounced back over the quarter, with revenue up 8%. That came from our new position in preferred provider tiers alongside 2 big payers at Doctors Hospital, much better economics on the new ISSSTELEON contract, broader B2B service packages, and more growth in the out-of-pocket segment. It also drove a 19% quarter-over-quarter lift in adjusted EBITDA and a 3.5 percentage point gain in margin. Looking year over year, EBITDA was up 23%. Please go to Slide 8. Peru's revenue growth came in at 9% and took a hit from revenue adjustments tied to higher reconciliation penalties that payers in that market put in place. Health care services revenue rose 7%, showing the benefits of our expanding scale, while commercial initiatives accounted for most of the gains in volume and utilization. Over on the insurance side, OncoSalud revenue climbed 12%, helped both by annual price increases and by growth in B2B plan memberships, including the 20,000 employees covered under a new group policy for the nation's judiciary that we won; we believe there's a widening opportunity for commercial initiatives to grow our share of the B2B portion of Peru's insurance market. First quarter adjusted EBITDA fell 3%, with margin shrinking 2.3 percentage points, hurt by those revenue adjustments I mentioned plus a delay in rebate recognitions and higher doctor compensation. If you set aside the revenue adjustments, Peru's adjusted EBITDA would have been up 7%. Let's head to Colombia on Slide 9. Revenue growth in Colombia picked up speed, rising 13% in the first quarter as we continued cutting our dependence on intervene payers and raised the share of risk-sharing agreements with payers, which went up 6 percentage points to 21% of Colombia's total revenue. Worth noting: revenue from intervene payers dropped 5 percentage points year over year, from 19% to 14%. Meanwhile, revenue from new payers came in 1.5x higher than the prior year quarter and now makes up 12% of total revenue. Our franchise in Colombia is clearly strong. We've handled the decline from last year's payer interventions well and come out growing more quickly. Adjusted EBITDA rose 7%, while margin declined 1.7 percentage points. That lower margin mostly reflects the bigger share of risk-sharing contracts and higher variable costs tied to greater volumes served in high complexity care. Now I'll hand the call to Gisele, who will walk through our results in more detail.

Gisele Ferrero executive
#3

Thank you, Suso. If we turn to Slide 11, you'll see we delivered robust top-line expansion throughout our regional network, with total sales hitting PEN 1.2 billion by the close of the quarter — that's a 10% rise year over year on an FX-neutral basis. Suso already mentioned this, and indeed the improvement stems from the strategic steps we took in Mexico and Colombia during the prior year, which helped us reshape our revenue mix into something more balanced, while Peru keeps drawing on its scale to seize the numerous opportunities still available in that market. Looking more closely at how Mexico bounced back, the main drivers were surgical procedures and oncology case volumes, up 15% and 32%, respectively, on a sequential basis; over in Peru, expanding B2B revenue played a key role, especially the 20,000 extra plan members we brought in via the group policy arranged with the country's judiciary, and within our health care network, better conversion rates pushed surgery volumes considerably higher, while emergency care rose 20% thanks to commercial programs aimed at corporate policyholders. Among all markets, Colombia posted the strongest expansion this quarter. Beyond the factors Suso already described, it's worth pointing out that capacity utilization came back to the 2024 level seen prior to the revenue rebalancing we carried out, which lowered our exposure to government intervene payers. Now let's look at adjusted EBITDA on Slide #12. Consolidated adjusted EBITDA fell 5% FXN, reflecting revenue adjustments in Peru as well as payroll growth in Mexico tied to greater compensation expenses for the recently appointed leadership team and to spending on recruiting and incentivizing physicians. In Colombia, compensation costs climbed relative to last year because the minimum wage went up 23%. Mexico's adjusted EBITDA bounced back, posting 19% growth quarter on quarter against the fourth quarter of 2025. Let's shift to adjusted net income on Slide #13. Highlighting the fundamental strength of Auna's regional platform, operating profit climbed 11% to PEN 155 million during the first quarter, but that gain was more than erased by noncash FX losses stemming from the Peruvian sol weakening past the protection threshold of the new hedging structure we established at the close of 2025. This reset should lower FX losses going forward, which would otherwise have come in larger this quarter. Slide 14, if you would. Free cash flow came to PEN 152 million, 2.6x what we recorded in the first quarter of 2025, driven mainly by a 45% rise in pretax operating cash flow, shown on the left side of the bridge. That speaks to our solid growth along with improved cash conversion, owing to disciplined working capital management and the supplier financing programs we've launched. Turning to the middle of the bridge, CapEx amounted to 3% of revenue and was mostly spent on infrastructure upgrades, medical equipment purchases, and expenses tied to rolling out the new hospital information system and ERP, largely in Mexico. That cash outflow was partly offset by an inflow from our ongoing effort to shift Auna Seguros' investment portfolio toward liquid securities. On the bridge's right-hand side, the PEN 88 million under financing activities consists of PEN 54 million for interest and hedge premium payments plus interest tied to working capital facilities, together with a PEN 34 million reduction in working capital borrowings. To finish up on this slide: because free cash flow is rising and interest payments are falling, we anticipate that cash flow generation after interest payments will be positive and will increase in 2026. That moves us toward our medium-term leverage goal of 3x, even as we keep putting money into our growth initiatives. Now let's turn to Slide 15. We entered 2026 with a stronger capital structure, helped by lower interest expenses, a better maturity profile, and less FX exposure. Once more, it's worth stressing that while our leverage ratio ticked up to 3.7x during the quarter, noncash FX effects were mainly behind that. After the refinancing exercise we completed last year, we have delivered roughly USD 8 million in annualized interest plus tax payment efficiencies, and cut short-term debt by 40% relative to the third quarter of 2025, before that refinancing exercise. As of quarter end, 55% of our debt was denominated in local currency, and the rest of the U.S. dollar-denominated debt was 85% hedged to the Peruvian sol. On top of that, 75% of our Mexican floating interest rate debt is hedged to fixed rate as well. Last, it's important to note that Auna holds roughly USD 175 million in revolving credit facilities, with only about $66 million drawn at present and the remaining $109 million still available. That wraps up my review of the quarter. Before we take questions, Suso has a few closing remarks to finish our presentation.

Jesús Zamora Leon executive
#4

Thank you, Gisele. Let me take a moment to walk through the main takeaways from what we covered today. To start, because of the considerable strides we've achieved with our growth plan and the robust fundamentals underpinning Auna's platform across the regions, we're confirming the guidance we gave for yearly revenue and EBITDA. With the 2025 base effect in mind, we anticipate that this growth will materialize during the second half of the year. There's substantial headroom for expansion in Peru, as our health care plans' growth shows. On top of that, the Trecca ambulatory Tower Lima, when it's finished, is set to broaden in a meaningful way the market we can serve in that country. Over the short term, we're rolling out efforts aimed at offsetting the hit from the revenue adjustments. We're not only cutting down our internal billing cycle so penalties ease going forward, but we'll also keep adding plan members and revenues within OncoSalud; those are simply the most immediate steps we've taken, and additional ones are on the way throughout our health care network; with a payer mix that has improved considerably in key service lines, Colombia is posting favorable performance figures. We look for growth and profitability to keep gaining strength. On top of that, cash flow stays a top priority, and expanding our risk-sharing businesses represents a sizable and distinctive opportunity for Auna. Mexico is set to keep getting stronger, powered by greater volumes, a better high complexity mix and expansion in our out-of-pocket segment. Finally, we anticipate operating cash flow along with organic cash flow will be robust as our integrated health care platform expands throughout our markets and as we gain from a capital structure that's more efficient, which additionally provides us the financial flexibility needed to push our growth strategy forward this year and past it.

Mauricio Cepeda analyst
#5

There are two things we'd like to ask. Starting with Mexico and the margin mix in that market. It looks like your focus keeps moving toward oncology and other service lines with faster growth. So for that segment, what should we expect for margins over the medium term? When investors look at oncology, should they assume it will structurally water down margins compared with the traditional core hospital business? Or can you see operating leverage emerging as volumes build? Then the second thing concerns Colombia — the political and regulatory risk. We noticed that exposure to intervened EPS has come down, and since dependence on EPS is smaller, that's clearly a positive. Still, we'd like to know if you anticipate more pressure if a future Colombian government turns out less favorable, or under any future regulatory conditions? And in a tougher policy scenario, how well protected is the current strategy for generating cash?

Jesús Zamora Leon executive
#6

Thanks; regarding the first one, in Mexico, to begin with, the revenue momentum is genuine. I'd say there's momentum in the way the new tier classifications for our hospitals there bring in a rising number of policy members. My sense is that Q2 will reflect a full quarter of this tier classification. The first Q didn't reflect all 3 months of it. ISSSTE price adjustments have sharply bettered the contract, along with the oncology ramp-up you brought up; so volume growth in chemotherapy and radiotherapy and in surgeries can already be seen, and margins will recover as utilization climbs. Also in the first Q '26, there are some nonrecurring severance and leadership payroll costs, which are small, but they do subtract a couple of margin points. And I see Mexico adjusted EBITDA up 19% against 4Q 2025. EBITDA rose 23% year on year. So for Auna on a consolidated basis, we're aiming for above 20% EBITDA margin. So in my view oncology has always been a richer business. And I think gradually it would add higher margins. But it's a scale business. It isn't — so at this point, we need to keep scaling. In oncology, our volumes are growing at double-digit rates. So we'll watch that lift the margins. On Colombia, a couple of points I'd make. My personal view is that I've seen — we've seen the worst of regulatory changes and political upheaval with President Petro. And under both scenarios from the current leading polls and candidates for the presidency, I think the Colombian health care sector won't deteriorate beyond what we've seen in 2025. So — and we are a unique player with these risk-sharing contracts and this with a unique positioning in high complexity. And we see payers grant us a preferred status in their payment list; and that's also critical. So it will not — I believe it will not affect — we're well prepared in Colombia, and it will not affect Auna in the near coming months in this full year. Gisele, I'm not sure whether you'd like to comment on Colombia and the receivables, and on how you view things — since you're nearer to the payers, including on the accounting side.

Gisele Ferrero executive
#7

Yes, Suso, thanks. Let me add to the two points from where I sit, beginning with Mexico and then moving to Colombia. I appreciate the question. When it comes to Mexico, Suso made it quite plain that the direction of revenue and the underlying trends we observe there are what allow us to bring margin back, and we are witnessing that carry into Q1 of this year as well, now that the ISSSTELEON contracts have been renegotiated. And to address how we view those structural margins in Mexico, it matters to highlight the rebound we are experiencing this quarter relative to what showed up in Q4. And although a few of the services falling under oncology—chemotherapy, for instance—might carry thinner margins, what we observe is that on a consolidated basis, we will keep restoring margins in Mexico through this year and into the next, getting nearer to those figures we have referenced previously as Mexico's structural margins of 30%. Turning to Colombia, I would add that Auna, in my view, has performed really well at rebalancing the mix of its revenue; and all that we have discussed on today's call regarding the rise in the share of risk-sharing contracts, plus the diversification away from intervened payers, has enabled us to generate the far more robust cash conversion observed across the last 12 to 18 months. And this was achieved as a consequence of the better revenue mix. So we are extremely, extremely optimistic about what lies ahead; regarding Colombia, we believe the new revenue mix will shield us from any effects we could encounter in how funds move through the sector and through universal health care. And clearly, as noted earlier, we are likewise shielded by how significant we are in high complexity services across the various cities where we operate and how that has caused payers to put Auna first when it comes to payment. And on top of that, we have had a lot of success with supplier financing initiatives too, so as to balance the entire cash conversion cycle.

Mauricio Cepeda analyst
#8

Just so I've got Mexico straight — if I followed you properly, that improvement in margin comes from operating leverage, correct? The way it looks to me, the incremental contribution from oncology would by nature be smaller than what core delivers. So that sort of margin, or that trajectory, would be…

Gisele Ferrero executive
#9

Right. I really appreciate the follow-up. Right, I'd say it comes from operating leverage and also from efficiencies in variable costs, and since we keep scaling, keep raising volumes, keep lifting occupancies, that's something we're actively managing too, and we do expect to keep seeing variable cost efficiencies in the years ahead.

Jesús Zamora Leon executive
#10

Gisele, one more thing from me on that: chemo does carry an appealing margin, yet radiation therapy's margin comes in even higher. Plus, we're bringing a brand-new site online — cutting-edge machinery, the sole such setup in Monterrey — which should be up and running in roughly 1 month to 1.5 months, I believe. That should give us a lift in volume too, and in all likelihood in margins as well.

Giovanni Vescovi analyst
#11

There are two things I'd like to ask. The first concerns how the company evaluates buybacks versus leverage. We do recognize that management targets 3x leverage. What we're trying to gauge is whether certain price levels make a repurchase plan more appealing — perhaps when the shares sit at $4.50. Then my second question is about ISSSTELEON. A 9-point rise in contribution margin showed up. We'd simply like to know whether you can share additional detail about further margin gains ahead, should any exist?

Jesús Zamora Leon executive
#12

Many thanks. Well, the Board keeps talking about this — the optimal deployment of cash — and has done so previously, without reaching a decision or a determination to deploy cash toward launching a buyback program. At present, no decision of that kind exists, though the Board is indeed deliberating actively over the optimal deployment of that cash to preserve value, and naturally, that would sit in line with the market and investors; and regarding your second point, margins at ISSSTELEON rose owing to our renegotiation of the entire contract, with improved volume and considerably improved margins. And even more crucially, something I'm unsure gets captured well within our public disclosures is that we hold complete control over how devices and pharma get used, ensuring we keep a handle on the cost of services provided to ISSSTELEON. Thus we're quite enthusiastic regarding that contract, given its considerably improved margins. As I mentioned earlier when answering the prior question, we hold the view that Mexico will keep enhancing its margins through scale; additionally, the fact that we're — we also gain from variable costs, yet scale plus fixed cost remedies for variable cost efficiencies will likewise keep improving, broadly speaking, across Mexico and, I believe, far more notably within our oncology practice there. Gisele, would you care to add anything regarding that last item?

Gisele Ferrero executive
#13

No, I think Suso covered it well.

Ana Maria Mora executive
#14

Thanks, operator. Morning, everybody. I'll begin with what came in via the webcast. We can't see anyone's name on our system today, but I still want to make sure the questions themselves get answered. Some of these have come up already, though if you've got anything further on these subjects, please speak up. Question one: could you share your thoughts on how the delay in medicine rebates has affected things? The second part of that question asks how we get to guidance, given that EBITDA would need a big second-half pickup. What's mainly driving that possible sharp acceleration?

Jesús Zamora Leon executive
#15

Okay. So I think I'll take the second question first, Gisele, and then you can cover how we're responding on the pharma rebate side. First off, there's something important I want to say again. We're heading into the rest of 2026 with trends that are getting better in all 3 markets. We can see a clear path to hitting our targets for the year. That's the reason we're reaffirming guidance for revenue and adjusted EBITDA, and it's backed by momentum in our revenue growth and cash flow. Mexico is definitely showing better trends, Peru is seeing revenue normalize, and Colombia, of course, keeps growing. On our adjusted EBITDA guidance, what we contemplated was that it would always be softer in the first half of the year, and we did expect only limited growth in the first and second quarters. Against that background, of course, what we did in the first quarter gives us confidence that we can deliver this full year adjusted EBITDA range. With our integrated health care model and the structural market opportunity that's still there across the 3 market positions, we're positioned to deliver on 2026 and, as I've said over and over, to move toward higher levels of sustained growth and profitability and, of course, margin improvements, as I've pointed out. So I think it matters to know that we see it, project it, and budget it as a second semester that's much stronger than the first semester. It also matters, and we've talked about this on earlier calls regarding the first Q, that the first Q is always a slower Q. That shouldn't surprise us at all. If we look back at everything since we came public, we always report the first Q as a softer Q. And then — Gisele, do you want to add anything here? Or would you rather go into the pharma rebate question?

Gisele Ferrero executive
#16

Sure, Suso — let me take the first portion of that question, the one about the pharmacy rebates that got pushed back, which we brought up earlier on this call. Essentially, this applies particularly to Peru, where certain pharma rebates have slipped into next year; none of that money has gone away; it has only been pushed back. Often this comes down to the way we handle inventories over the course of the year, but it ought to land as a shift into the following year.

Ana Maria Mora executive
#17

Thanks, Gisele. Let's turn to the next question. Can you give us more detail about the revenue adjustments and the postponed pharmacy rebates in Peru? Would you characterize those as one-time occurrences, or as something within a wider pattern that might continue in the future?

Jesús Zamora Leon executive
#18

Gisele, do you want to take that one?

Gisele Ferrero executive
#19

Absolutely. Regarding the second portion of your question, that concerns the pharmaceutical rebates, and then perhaps I can address the first portion regarding the revenue adjustments we observed in Peru during this quarter. As we noted earlier on this call, this ties to what we've experienced with respect to specific penalties imposed by certain insurance payers connected to billing, along with the reality that a number of billing cycles have run somewhat longer, plus certain settlement agreements that are presently under negotiation. Is this a one-time item? Should we anticipate it will recur? It's worth emphasizing, and as we've stated in prior quarters, that Auna has been diligently focused on its cash conversion and revenue cycle management processes across all 3 countries, and Peru clearly is not an exception. Our internal billing cycle has been substantially shortened over the past 12 months, which will assist in shielding us amid the present market environment in Peru, where insurance payers, given the elevated level of MLRs, have grown far stricter regarding controls and the levying of penalties when they observe billing days rising. So it matters to point out that we are ready to handle this market environment. We've been working on it proactively for the last 12 months. And that ought to help shield us, allowing us to lessen this impact in upcoming quarters and be better positioned as we enter the second half of the year.

Ana Maria Mora executive
#20

Appreciate that, Gisele. Moving on to the next question — at what point do you anticipate a turnaround in Mexico margins? And which main factors ought to underpin margin growth consistent with the guidance you've given?

Jesús Zamora Leon executive
#21

As far as the general trajectory goes, I believe I addressed that when I spoke earlier. Still, it seems reasonable to state that we expect better margins over the rest of this year, and even more significantly, throughout the second half. This rests on the points we made previously: oncology building volume, which spreads out fixed expenses, along with cost efficiencies on the variable side, and that applies not just to oncology but to our other practices as well. So at present, with the data we are gathering, we are clearly witnessing margin gains in Mexico, and, as I mentioned earlier, the ISSSTELEON contract is likewise showing a substantially better margin.

Ana Maria Mora executive
#22

Thanks, Suso. Now, on to the supplier financing programs. Could you give us more detail about the supply and financial steps that have been put in place in those 3 regions?

Gisele Ferrero executive
#23

Absolutely, and thanks for asking. So yes, we have taken an active approach to handling our working capital, particularly when it comes to the programs around supplier financing. We've had several efforts underway in that area. Regarding Peru, the biggest piece has involved some fresh working capital arrangements set up with particular banks. Those structures, on top of what existed before, have allowed us to stretch our accounts payable days further, and that helped bring about a working capital improvement during the quarter. In both Colombia and Mexico, we've likewise managed to lengthen the number of days we take to pay, and we've also grown the volume of factoring lines we are drawing on.

Ana Maria Mora executive
#24

Thanks, Gisele. Our next question concerns FX impact, and I'll combine it with another one. Would you expand on how FX affected the Q1 results and what the plan is moving forward? In addition, could you talk about the FX loss shown in the quarterly income statement and the sizable OCI FX gain that appears through the equity statement?

Gisele Ferrero executive
#25

Certainly, so during 2025, currency movements affected the numbers we reported. That stemmed from what happened a year earlier, when the Peruvian sol strengthened past the call spread hedges we held prior to completing the refinancing. After we finished that refinancing during the fourth quarter of last year, we likewise adjusted the FX thresholds on those call spread hedges. As a result, the band we now use sits much closer to where FX currently trades, which ought to lessen currency swings over the next several quarters. What showed up in Q1 of this year came from the Peruvian sol weakening slightly relative to the fresh call spread hedge, though the effect clearly would have been far bigger had we left the levels on our hedging instruments untouched; that explains why we anticipate reduced FX volatility for the remainder of the year compared with what we might have experienced previously. Regarding the second portion of your question about FX effects landing in OCI, you are right. Accounting hedge treatment does apply to our hedging instruments, so their outcomes get accumulated within the OCI accounts as well; I believe that addresses both pieces of the question.

Ana Maria Mora executive
#26

Thanks, Gisele. Our next question concerns Colombia, and I'll read it out. This is my one question: PGP revenue in Colombia got to 21% of segment revenues, which is up from 15% in 1Q '25. The adjusted EBITDA margin, though, narrowed to 11.4%. With PGP continuing to scale, what's your expectation for how the margin profile develops from here?

Jesús Zamora Leon executive
#27

Thanks. Broadly speaking, I want to convey that margins in Colombia are holding steady. At Auna, our approach involves initially securing volume at appealing margins, and after that we expand that model so margins rise. As I said, referencing ISSSTELEON and the bulk of our practices, that captures a portion of our strategy across the 3 countries, and especially within Colombia. Naturally, the risk sharing operation in Colombia, working with solid payers, accounts for roughly 20% — 21% of revenues. As noted in the earnings release, of course, intervene payers have declined. Our risk sharing operation delivers strong predictability, cash predictability, and a shorter working capital cycle, without question. There is definitely a modest initial effect on margin. Yet, as I noted earlier regarding the playbook, and on top of that, as we refine clinical pathways in Colombia, say for over 3 million individuals, 3 million covered lives, we observe margin expansion via cost dilution, covering both fixed and variable. Thus we anticipate recovering a couple of points from the margin dilution typically experienced when PGP programs begin; and keep in mind, the majority of PGP program growth took place during 2025. Gisele, would you like to chime in on this?

Gisele Ferrero executive
#28

Yeah, I'd say that's a solid way to put it, Suso. One thing I'd tack on is that in Colombia, Q1 typically brings us thinner margins — just wanted to make that clear too. Like Suso said, we ought to be looking at margins holding steady relative to what we've seen over the past year, and on top of that, I think they'll be climbing above those levels. That ties back to what Suso brought up: we're rolling out the new risk-sharing models, and we keep working to stabilize those populations. So for this year, margins should stay level with what we were seeing in the back half of last year.

Ana Maria Mora executive
#29

Moving on, my next question concerns Mexico. Nice work on a solid quarter. Could you speak to the effort to achieve universal health care there by 2027? And is that probably going to shift how competition plays out and what we can target?

Jesús Zamora Leon executive
#30

Sorry, I had a glitch there. Ana, can you repeat, please?

Ana Maria Mora analyst
#31

Absolutely. Nice work on the quarter. Could you speak to the drive toward universal health care in Mexico by 2027? And is that probably going to shift how competition plays out in the target opportunity?

Jesús Zamora Leon executive
#32

Yeah. So, the current administration has launched what I'd call a genuinely compelling effort. We're feeling pretty positive about it, since we operate as a participant in Colombia—one of the more advanced markets for universal health care—and we've watched our own business expand, moving further into high complexity. When we look at Mexico right now, with ISSSTELEON and a few other state-level institutions, there's a widening chance to provide additional services to the state. That's a theme that keeps gaining momentum. Through Trecca in Peru, we're developing a B2G capability. Universal health care isn't the same as the state handling every single thing. What it actually means is that the state aims to guarantee the whole population gets covered, whether through a government-run platform or one run by the private sector. Our belief is that this will expand our business; we consider it a truly appealing opportunity; and we're already witnessing the spillover, the enormous spillover coming from the state sector along with its inability to get services out to citizens. So from our standpoint, this is a chance rather than a high-risk scenario that would unfold in some other way.

Ana Maria Mora executive
#33

Thanks, Suso. Moving on to the next question: could you give us some insight into how costs break down between fixed and variable in every country?

Gisele Ferrero executive
#34

Absolutely. If you examine the cost of goods sold category, specifically what it costs us to deliver services in every one of our markets, that affects gross profit at Auna, and variable expenses account for over 60% of the entire COGS structure throughout all 3 geographies.

Ana Maria Mora executive
#35

Thanks, Gisele. On to the next question: what's the reason the underlying operating metrics aren't expanding more on their own? Our thinking was that the market had room for more penetration, and it seemed only natural that your assets would deliver organic growth in every market where you operate.

Jesús Zamora Leon executive
#36

Yeah, that’s a great question. I’d say the markets are underpenetrated, mainly when it comes to players—formal institutional players capable of providing integrated services to the population; across most of our operations, we’re seeing organic growth. In Mexico, there have been some dislocations, as we’ve talked about before, but that’s the underlying theme behind our thesis in the 3 countries. Organic volume is going to keep growing. We see it in high-complexity areas like surgeries, obviously, chemotherapy, and radiotherapy. That growth is what we view as the primary driver of our continued growth over the years. Gisele, would you like to add anything on that?

Gisele Ferrero executive
#37

I'd say you captured that nicely, Suso.

Jesús Zamora Leon executive
#38

I'd like to add something for Annie regarding what she asked earlier — the universal health care possibility in Mexico is genuinely fascinating. Among the initial goals this initiative has is bringing every one of the state's separate institutions that deliver services to residents together beneath a single umbrella, so that residents can access those services more easily; and it's quite evident that this arrives alongside a significant push toward public-private partnerships. So once more, I'm quite enthusiastic about the B2G sector's future in Mexico.

Gisele Ferrero executive
#39

To build on that, the thing they rolled out in Mexico isn’t universal health care. A more accurate label would be the Servicio Universal de Salud, a push to bring together access through the country’s biggest public health care systems — the IMSS, ISSSTE, and IMSS-Bienestar — so that individuals are able to get care at public facilities no matter which institution they’re affiliated with.

Ana Maria Mora executive
#40

Moving on to the next question: what's the right way for us to consider revenue for each patient treatment over the next several years? In your markets, will those figures rise above inflation, below it, or in line with it?

Jesús Zamora Leon executive
#41

Okay, so this is a question about the future, so what I say is also forward-looking. When it comes to how we steer Auna on the topline, we look at price, volume, and mix. Mix has to do with whether cases are highly complex or not. We keep putting more emphasis on GRDs, which serve as a diagnostic index for high complexity. That will certainly lead to a higher patient — a higher revenue per patient treatment. And across the 3 countries, we handle inflation effectively by at minimum raising our prices enough to match medical inflation, and at times slightly beyond that. This has been true for many, many years. So my view is that growth lands at purchasing power parity, or somewhat above it, in the 3 markets.

Gisele Ferrero executive
#42

I'll add to what Suso said there. It matters a great deal that, as you point out, we take an active hand in managing price, mix and volume so that we get the value creation equation that comes out of it; and ultimately, as Suso noted, we've done well — if you examine our results over a medium and long-term horizon — at passing through that medical inflation, and we've also done well at expanding access, correct? So ultimately, we also believe that we — looking at this in purely numerical terms — will be growing over a medium and long-term horizon at a rate above inflation, though much of that also relates to mix and efficiencies.

Ana Maria Mora executive
#43

Thanks, Gisele. Thanks, Suso. And just to close things out, could you give us an update on how construction is going at Torre Trecca, or on when the addendum process gets underway.

Jesús Zamora Leon executive
#44

Alright. So during this month, we achieved considerable advancement on Project Trecca across every design and definition. Plus we — the committee, our internal committee, has already settled on the construction consortium; and I believe it has either been granted or is going to be granted this week. So a concession consortium contract will be granted, and right away we'll begin construction; it matters to acknowledge that this construction process takes 24 months. We think we can finish it somewhat faster than that, somewhere between 18 months and 24. And like I said earlier, the award will happen this week.

Ana Maria Mora executive
#45

Alright, thanks, Suso. That brings us to the close of today's queue of questions. I appreciate everyone's time and involvement, and Suso, I'll turn it over to you now for any closing remarks.

Jesús Zamora Leon executive
#46

I appreciate that, Annie. What I'd like to share with the investor community is that we feel great about the progress underway. At the same time, we recognize that on occasion we've come forward with news that caught people off guard, such as the revenue reconciliations in Peru. Going forward, our performance will improve significantly. We'll ensure surprises are kept to a minimum, and our approach will be far more intentional and consistent. Our goal is to make the narrative easier to follow, so that anyone tracking us — investors, and naturally, research institutions as well — can grasp what we're doing more readily, without the numerous adjustments we currently carry. This has our full attention. Over the next year, I believe we can produce something far easier to absorb. Yet beneath all of that, growth in our core business continues, and that matters a great deal. We've regained our footing, and we will expand. Our margins will get better, and the services we provide to the communities and populations we serve will become more numerous and higher in quality. Many thanks to all of you, and I'm grateful for the chance to share these reflections — mine or ours — with you folks, as well as to take your questions.

Operator operator
#47

This concludes today's conference call. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Auna S.A. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Auna S.A. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.